'Why we do What we do in Cardiology'

'Why we do What we do in Cardiology'

I am Dr. Bishnu Subedi. I am a cardiologist in the United States. In the era of evidence-based medicine, our practice is usually guided by a scientific study, expert society statements, or clinical guidelines. In this podcast series, I intend to highlight some of these practice-changing articles in the field of cardiology from past and present.

Tämä podcast on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi podcastin jaksot saattavat sisältää mainontaa.

Jaksot(35)

Acute CHF: GDMT Up-titration After Hospitalization for Acute HF (STRONG-HF Trial)

Acute CHF: GDMT Up-titration After Hospitalization for Acute HF (STRONG-HF Trial)

Study: STRONG-HF trial examined rapid up-titration of heart failure medications (GDMT) after hospitalization. Goal: Reach optimal GDMT doses within 2 weeks after discharge. Findings: Over 90% of patie...

19 Tammi 20245min

LIPIDS: Treat to Target or with High Intensity (LODESTAR Trial)

LIPIDS: Treat to Target or with High Intensity (LODESTAR Trial)

Key Points from "Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR": The study compares two strategies for managing LDL cholesterol in coronary artery disease (CAD): Treat-to-t...

15 Tammi 20244min

Tricuspid Regurgitation: TEER for severe TR (Triluminate Pivotal Trial)

Tricuspid Regurgitation: TEER for severe TR (Triluminate Pivotal Trial)

Key Points of the Study: T-TEER with the TriClip device significantly improved health status in patients with severe tricuspid regurgitation (TR) compared to medical therapy alone. This improvement wa...

12 Tammi 20243min

PAD: PROMISE II Trial: Deep-Vein Arterialization Shows Promise for No-Option CLTI Patients.

PAD: PROMISE II Trial: Deep-Vein Arterialization Shows Promise for No-Option CLTI Patients.

Key Points from PROMISE 2 Trial: • Problem: 20% of CLTI patients have no revascularization options, leading to amputations. • Solution: Transcatheter arterialization of deep veins creates an artery-to...

8 Tammi 20242min

Degenerative MR: Two Choices now for Mitral Transcatheter Repair (TEER): Clasp IID Trial

Degenerative MR: Two Choices now for Mitral Transcatheter Repair (TEER): Clasp IID Trial

Key Points from this trial: The CLASP IID trial, the first randomized controlled trial comparing the PASCAL system and the MitraClip system in prohibitive-risk patients with significant symptomatic d...

5 Tammi 20243min

Sinus Node Disease: DANPACE II trial: Study Debunks Pacing Myth: Minimizing Pacing Doesn't Curb A-Fib

Sinus Node Disease: DANPACE II trial: Study Debunks Pacing Myth: Minimizing Pacing Doesn't Curb A-Fib

Key points of the DANPACE II study on atrial pacing and atrial fibrillation in sinus node dysfunction: 1. Minimizing atrial pacing in pacemakers doesn't prevent atrial fibrillation (AF): • 46% of pati...

1 Tammi 20243min

Major Trends in Cardiology from 2023

Major Trends in Cardiology from 2023

Major Trends: Independent Medical Board: Cardiologists seek a new board separate from the ABIM due to concerns with MOC requirements. Scope of Practice Debates: Tensions arise over advanced nurse p...

31 Joulu 20234min

CAD: Coronary Artery Disease Updates in 2023

CAD: Coronary Artery Disease Updates in 2023

Key Points of Coronary Artery Disease Studies in 2023: • ORBITA-2: Confirmed PCI's role in relieving angina symptoms for stable patients. • SELECT: Semaglutide (Ozempic) reduced cardiovascular events ...

25 Joulu 20236min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
tiedenaiset-podcast
psykopodiaa-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
terapiassa
meditaatiot-suomeksi
rss-pt-paahtio
rss-pitaisko-erota
fitnessvastaanotto
rss-seksicast
voi-hyvin-meditaatiot-2
rss-uplevel-by-sonja-hannus
onnen-kuplia
paritellen
rss-vapaudu-voimaasi
rss-kuumilla-aalloilla
katilon-kahvitunti
junnut-pelissa
rss-rentoudu-podcast-rentoutumiseen-hanna-viljanmaa
rss-sanelunpurku-podcast